Tianjin Medical University Cancer Institute And Hospital

This study is testing a new combination of two targeted drugs, SHR-A1811 and pertuzumab, given before surgery for a specific type of breast cancer that is both hormone receptor-positive (HR+) and HER2-positive. The goal is to see if this approach can effectively shrink or elimina…

This study is testing which of two drug combinations works better to shrink tumors before surgery in people with HER2-positive breast cancer. About 188 participants will receive either the standard three-drug combination plus a new drug called QL1706, or the standard combination …

This study is testing whether taking Iruplinalkib tablets after surgery can help prevent early-stage lung cancer from returning. The trial will involve 28 patients who have had surgery for a specific genetic type of lung cancer and have certain risk factors. Researchers will trac…

This study is testing whether adding a new immunotherapy drug (Retlirafusp alfa) to standard chemotherapy helps people with a type of stomach cancer where the stomach meets the esophagus. The goal is to shrink the tumor before surgery and then use the new drug after surgery to tr…

This study is testing if adding an over-the-counter allergy medication (diphenhydramine) to standard chemotherapy and immunotherapy improves results for people with operable non-small cell lung cancer. About 120 participants will receive the drug combination before surgery and th…

This study tests whether adding low-dose radiation to immunotherapy and chemotherapy before surgery helps patients with esophageal squamous cell carcinoma who didn't respond well to previous treatment. About 48 participants will receive radiation followed by two cycles of drug tr…

This study is testing whether adding two newer drugs (bemotuzumab and anlotinib) to standard chemotherapy and radiation can better control extensive-stage small cell lung cancer. About 25 patients who haven't had prior treatment will receive the combination therapy in phases, sta…

This study is testing whether combining two drugs, entinostat and oral paclitaxel, can help control advanced breast cancer that is hormone receptor-positive and HER2-negative. It is for people who have already tried 2-4 other treatments, including specific hormone therapy and che…

This study is testing a new combination of four medicines for children whose neuroblastoma has come back or hasn't responded to other treatments. The main goal is to see if this combination can effectively control the cancer. Researchers will also closely monitor the safety and s…

This study is testing whether a new two-in-one immunotherapy drug (QL1706) works better when given alongside a precise, high-dose form of radiation (SBRT) for people with early-stage non-small cell lung cancer. The main goal is to see if this combination can help control the canc…

This study is testing a new combination of immunotherapy and chemotherapy drugs given before surgery for a type of esophageal cancer. The goal is to see if this pre-surgery treatment can completely eliminate cancer cells in the removed tumor and improve long-term results. It will…

This study is testing whether a combination of four cancer drugs can help control aggressive solid tumors in children and teenagers when standard treatments have failed. It will involve about 33 young patients (ages 3-18) at a single hospital in China. The main goal is to see if …

This study aims to determine which treatment sequence works better for Chinese patients with advanced kidney cancer that has spread. Researchers will compare two approaches: starting with drug therapy alone followed by drug-plus-immunotherapy, versus starting with the combination…

This study is testing a new, personalized first treatment for older adults with mantle cell lymphoma, a type of blood cancer. It combines chemotherapy and targeted drugs, then adjusts the plan after four cycles based on how well the cancer is responding. The goal is to better con…

This study aims to see if personalized, first-line treatment combinations can better control an aggressive form of lung cancer. It will enroll 165 adults with extensive-stage small cell lung cancer who haven't had prior treatment for advanced disease. Doctors will test different …

This study is testing a new two-in-one immunotherapy drug called QL1706, given with chemotherapy before surgery for early triple-negative breast cancer. The goal is to shrink tumors and see if some patients can safely skip a type of chemotherapy that can harm the heart long-term.…

This study tests whether a drug called fluzoparib can help control advanced triple-negative breast cancer after initial treatment. It will involve 72 patients whose cancer responded to platinum-based chemotherapy but could still return. The goal is to see if taking fluzoparib as …

This study is testing a new combination treatment for people with a type of esophageal cancer that can be surgically removed. Before surgery, patients will receive a two-part immunotherapy drug along with a chemotherapy drug to try to shrink the tumor. The main goal is to see if …

This study is testing a combination of three drugs (utidelone, bevacizumab, and sometimes etoposide) to treat cancer that has spread to the brain from lung or breast tumors. It will involve 56 patients to see if this approach can shrink brain tumors and control the disease. The g…

This study is testing a new combination of immunotherapy and chemotherapy drugs to see if it can shrink tumors enough for surgery in people with certain liver and gallbladder cancers. The goal is to turn tumors that are currently difficult or impossible to remove surgically into …

This early-stage study is testing the safety of an experimental cell therapy called CHT101 for adults with recurrent or progressive malignant brain tumors. The trial will enroll 30 participants to see how their bodies handle the treatment and look for early signs of effectiveness…

This study is testing whether adding a new drug called tunlametinib to standard chemotherapy and another targeted drug works better for advanced pancreatic cancer. It's for adults who haven't had any prior cancer treatment. The goal is to see if this combination can shrink tumors…

This study is testing whether adding a drug called gecacitinib to two other cancer drugs (donafenib and a PD-1 inhibitor) can help control advanced liver cancer that has started growing again after initial immunotherapy. It will enroll 35 adults to see if this combination is safe…

This study is testing whether a combination of two drugs, sacituzumab tirumotecan and tagitanlimab, can help control advanced triple-negative breast cancer that has worsened after initial treatment. It will involve about 47 patients whose tumors test positive for a marker called …

This study is testing whether a combination of two drugs, sacituzumab govitecan and toripalimab, can shrink tumors in patients with a specific type of lung cancer before they have surgery. The goal is to see if this pre-surgery treatment helps remove more of the cancer and lowers…

This study aims to observe how effective and safe the drug pyrotinib is for treating advanced HER2-positive breast cancer in a real-world setting. It will enroll 500 patients who are starting this treatment for the first time, following their progress as they receive care from th…

This study aims to find the better first treatment for people with a specific type of lung cancer (EGFR-mutated NSCLC) that has spread to the brain. It will compare a higher dose of the targeted drug furmonertinib taken alone against a lower dose of the same drug combined with tw…

This study is testing if adding a drug called surufatinib to standard chemotherapy helps people with high-risk pancreatic cancer that can be removed by surgery. The goal is to see if the three-drug combination shrinks tumors better before surgery, leading to more successful opera…

This study is testing a new two-drug combination for people with a specific type of advanced lung cancer that has worsened after their first treatment. It aims to see if the treatment can shrink tumors and control the disease. The trial will enroll about 31 patients to closely mo…

This study is testing a new combination treatment for people with advanced bile duct cancer in the liver that cannot be treated with surgery. The treatment combines three approaches: chemotherapy delivered directly to the liver, a daily pill that targets the tumor's blood supply,…

This study is testing a new combination of drugs for people with advanced kidney cancer that has worsened after their first treatment. It combines an immunotherapy (iparomlimab and tuvonralimab) with one of two targeted drugs (lenvatinib or axitinib). The main goal is to see if t…

This study is testing whether combining two drugs, sacituzumab tirumotecan and toripalimab, can help control advanced triple-negative breast cancer that has spread and cannot be removed by surgery. It will involve about 41 women who have not yet received treatment for their advan…

This study is testing whether giving two drugs, tislelizumab and lenvatinib, before surgery can help people with liver cancer that can be removed by surgery but is likely to come back. The goal is to see if this treatment can lower the chance of the cancer returning and help pati…

This study is for people with advanced esophageal cancer that cannot be surgically removed. After completing initial treatment with chemotherapy, immunotherapy, and radiation, patients whose cancer is stable or shrinking will be randomly assigned to either receive an extra immuno…

This study is testing if a drug called romiplostim N01 can help breast cancer patients recover their platelet counts after chemotherapy. Low platelets (thrombocytopenia) are a common side effect that can delay cancer treatment. The study will see if weekly injections of the drug …

This study is for people with a type of breast cancer (HER2-negative) that did not shrink enough after two rounds of standard chemotherapy. Researchers want to see if adding an immunotherapy drug (toripalimab) and a very precise, high-dose radiation treatment can help eliminate m…

This study is testing a new pain medication called Anrikefon for people recovering from laparoscopic stomach cancer surgery. The goal is to see if it effectively manages pain while reducing the need for strong opioid painkillers and their common side effects like nausea and vomit…

This study tests which of two drug combinations works better at preventing nausea and vomiting in breast cancer patients receiving T-DXd therapy. 120 participants will receive either the standard anti-nausea treatment or an experimental combination over two treatment cycles. The …

This study looks back at 300 patients with a type of lung cancer who received immunotherapy before surgery but still had cancer cells left after the operation. Researchers will analyze the leftover tumor tissue using advanced genetic testing to search for hidden genetic reasons w…